STOCK TITAN

23andMe Holding Co. - ME STOCK NEWS

Welcome to our dedicated page for 23andMe Holding Co. news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co. stock.

23andMe Holding Co. Class A Common Stock (NASDAQ: ME) is a leading genetics-led consumer healthcare and biopharmaceutical company. Founded in 2006, 23andMe specializes in personal genome services through DNA analysis technologies and interactive web-based tools. The company’s core service allows individuals to gain deep insights into their genetic ancestry, health predispositions, and phenotypic traits.

23andMe's mission is to personalize healthcare by supporting meaningful discoveries through genetic research. The company's primary revenue comes from its Consumer and Research Services segment, which includes the sale of direct-to-consumer personal genome services (PGS). This involves shipping DNA collection kits to users, who can then access detailed reports on their genetic makeup through 23andMe’s platform.

The company also has a Therapeutics segment that focuses on leveraging genetic data to develop new treatments. Notably, 23andMe presented positive Phase 2 safety and efficacy data from their anti-CD200R1 antibody, 23ME-00610, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Despite its groundbreaking work, 23andMe recently faced a significant data breach, affecting approximately 7 million users. Hackers specifically targeted the genetic information of Jewish and Chinese customers, selling the data on the dark web. This incident has led to a class-action lawsuit and ongoing investigations.

In research, 23andMe has also made significant strides. For example, the company conducted the world's largest study on the LRRK2 G2019S variant linked to Parkinson’s disease, with support from The Michael J. Fox Foundation. Findings from this study revealed new insights into the variant's impact and its prevalence in various populations, including unexpected hotspots in Latin Caribbean communities.

23andMe continues to expand its offerings, providing reports that calculate genetic likelihood for conditions like bipolar disorder, anxiety, and depression for its 23andMe+ Premium members. These reports are based on polygenic risk scores (PRS) developed through the company’s extensive research database.

With a strong commitment to advancing personalized healthcare and continuous innovation in genetic research, 23andMe remains a significant player in the biotechnology and consumer healthcare sectors.

Rhea-AI Summary

23andMe and Nightingale Health have announced a strategic collaboration to pilot Nightingale’s blood metabolomics panel with 23andMe members. The partnership aims to enhance preventive health measures by integrating blood testing with 23andMe’s genetic services. The pilot will offer up to 5,000 23andMe+ Premium and Total Health members free access to Nightingale’s Remote Health Check, which measures biomarkers related to disease risk. The initiative seeks to combine genetic data with blood biomarkers to improve health predictions and interventions. The collaboration underscores both companies' commitment to proactive health management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
none
-
Rhea-AI Summary

On June 14, 2024, 23andMe (NASDAQ: ME) disclosed a data breach from December 2023 affecting 7 million users. Hackers targeted the personal genetic information of Jewish and Chinese customers, which was sold on the dark web. The breach was not fully disclosed to the affected customers, sparking a class action lawsuit. Hackers leaked 1 million Jewish profiles and 350,000 Chinese profiles in retaliation for global events and specific requests. The breach potentially endangers the safety of these individuals. 23andMe initially blamed recycled login credentials for the breach and delayed full disclosure until December.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary

On June 11, 2024, 23andMe (NASDAQ:ME) revealed a December 2023 data breach that compromised the personal information of 7 million users. Hackers specifically targeted the genetic data of Jewish and Chinese customers, hiding these details from the public. The breach led to a class action lawsuit, alleging that 23andMe failed to inform affected users. The hackers sold the stolen data on the dark web, posing significant safety risks, especially for Chinese citizens. The company blamed recycled login credentials for the breach and delayed its full disclosure until December 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
Rhea-AI Summary

23andMe (NASDAQ:ME) experienced a data breach in December 2023, impacting around 7 million users. Hackers targeted the genetic information of Jewish and Chinese customers, selling it on the dark web. Despite knowing the specifics, 23andMe did not inform affected customers about their personal data being compromised. This resulted in significant safety concerns, especially for Jewish and Chinese users. A class-action lawsuit has been filed against the company, accusing it of negligence and failing to protect user data. The law firm Levi & Korsinsky is investigating potential compensation for affected users.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
none
-
Rhea-AI Summary

In December 2023, 23andMe (NASDAQ:ME) faced a significant data breach, impacting about 7 million users. Hackers specifically targeted personal genetic data of Jewish and Chinese customers. This sensitive information was sold on the dark web, a detail that 23andMe reportedly hid from affected users. The breach's severity is highlighted by a class action lawsuit claiming that over 1 million Jewish customers' data was leaked following an Israel-Hamas conflict and 350,000 Chinese customers' data was released on request. The lawsuit accuses 23andMe of failing to notify all compromised users or disclose the targeting of Jewish and Chinese customers. The breach has raised serious safety concerns, especially regarding the Chinese government's potential actions against its citizens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
Rhea-AI Summary

23andMe (Nasdaq: ME) has launched a new genetic report for Bipolar Disorder, targeted at 23andMe+ Premium members. This report uses a polygenic risk score (PRS) model to determine an individual's likelihood of developing bipolar disorder based on thousands of genetic variants, ancestry, and birth sex. Bipolar disorder affects about 4.4% of American adults, and genetics are a significant contributing factor. This new report, developed from 23andMe's proprietary research database, aims to help users identify potential symptoms early and manage their mental health better. It follows other mental health PRS reports such as Anxiety, Panic Attacks, and Depression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
Rhea-AI Summary

23andMe (NASDAQ:ME) was hacked in December 2023, compromising the data of approximately 7 million users. The breach specifically targeted Jewish and Chinese users, whose personal genetic information was sold on the dark web. The lawsuit claims that 23andMe did not inform users about the targeted nature of the breach and the sale of their data. The hacker, using the alias 'Golem,' leaked lists of Jewish and Chinese users in retaliation for current events, including the Israel-Hamas conflict. The company has been accused of shifting blame to users for using recycled passwords and failing to report the full extent of the breach promptly. Levi & Korsinsky, LLP is investigating potential compensation for affected customers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
none
-
Rhea-AI Summary

23andMe Therapeutics has announced positive preliminary Phase 2 results for 23ME-00610, an anti-CD200R1 antibody, at the 2024 ASCO Annual Meeting. The study showed a confirmed partial response in a patient with pancreatic neuroendocrine cancer and qualitative clinical benefit in an ovarian cancer patient. The treatment demonstrated acceptable safety and tolerability, meeting the specified pharmacology targets at 1400 mg dosed every three weeks. Over 70% of patients had detectable CD200 in their tumors, suggesting it as a potential biomarker. The study involved 32 patients with advanced neuroendocrine and ovarian cancers, highlighting promising safety profiles and potential anti-cancer effects. No severe treatment-emergent adverse events were reported, and immune-related adverse events remained mild. More research is needed to solidify these findings and explore combination therapy possibilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
-
Rhea-AI Summary

23andMe (NASDAQ:ME) faced a significant data breach in December 2023, affecting 7 million users. A recent class action complaint reveals that hackers targeted the genetic information of Jewish and Chinese customers, selling this data on the dark web. The breach was allegedly hidden from affected users by the company, who did not disclose the specific targeting of Jewish and Chinese users. The data leak occurred on October 1, 2023, and included sensitive information such as phenotype and health data. This incident has led to significant safety concerns for the affected individuals. Legal firm Levi & Korsinsky, LLP is investigating the breach and potential compensation for affected users.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
Rhea-AI Summary

23andMe (NASDAQ:ME) suffered a significant data breach in December 2023, impacting approximately 7 million users. Recent revelations from a class-action lawsuit indicate that hackers specifically targeted the genetic information of Jewish and Chinese customers, which the company allegedly concealed from the affected users. The hackers leaked lists of this sensitive information on the dark web, posing significant security risks to those individuals. 23andMe has been criticized for its delayed and incomplete disclosure of the breach's extent, and the lawsuit seeks compensation for those affected.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.95%
Tags
none

FAQ

What does 23andMe specialize in?

23andMe specializes in personal genome services, providing individuals with insights into their genetic ancestry, health predispositions, and phenotypic traits.

How does 23andMe generate its revenue?

The company primarily generates revenue through its Consumer and Research Services segment, which involves the sale of direct-to-consumer personal genome services.

What recent research has 23andMe conducted?

23andMe conducted the world's largest study on the LRRK2 G2019S variant linked to Parkinson’s disease, uncovering new insights and variant prevalence in various populations.

What was the recent data breach involving 23andMe?

In December 2023, 23andMe experienced a data breach affecting approximately 7 million users. Hackers targeted and sold the personal genetic information of Jewish and Chinese customers on the dark web.

What are 23andMe's key offerings for 23andMe+ Premium members?

23andMe+ Premium members have access to reports that calculate genetic likelihood for conditions like bipolar disorder, anxiety, and depression, based on polygenic risk scores (PRS).

Who are 23andMe's main partners in research?

23andMe collaborates with renowned experts and organizations, including The Michael J. Fox Foundation for Parkinson’s Research, to conduct groundbreaking studies.

What is 23andMe's vision?

23andMe aims to personalize healthcare by making meaningful discoveries through genetic research and empowering individuals with information about their genetic makeup.

What is 23ME-00610?

23ME-00610 is an anti-CD200R1 antibody developed by 23andMe, currently showing promise in Phase 2 clinical trials for its efficacy and safety in treating certain cancers.

How does 23andMe protect user data?

23andMe employs various security measures to protect user data, though the recent data breach has highlighted the need for increased vigilance and transparency.

How can customers participate in 23andMe's research?

Customers can participate in 23andMe’s research by consenting to share their genetic and health information, helping to further scientific understanding and discoveries.

23andMe Holding Co.

Nasdaq:ME

ME Rankings

ME Stock Data

238.17M
323.54M
3.52%
38.97%
5.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO